Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its IPO on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. Financial Performance - Wealthfront reported net deposit outflows of $208 million for its first quarterly results as a public company, a significant decline from the $874 million in inflows during the same period the previous year [4]. - CEO David Fortunato attributed the outflows to falling interest rates and highlighted the strategic importance of the company's new home-lending business [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of BellRing Brands, Inc. about a class action lawsuit related to misleading statements regarding the company's sales growth and competition impact [1]. Group 1: Allegations and Class Action Details - The class period for the lawsuit is from November 19, 2024, to August 4, 2025 [1]. - Allegations include that BellRing Brands claimed sales growth was due to increased consumer demand and various positive factors, while downplaying competition's impact on demand [1]. - The company asserted it had a "competitive moat" in the ready-to-drink category, suggesting that competition was not significantly affecting its market position [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by March 23, 2026 [1]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [1]. - Participation in the case does not incur any costs or obligations for the shareholders [1].

Core Viewpoint - PennyMac Financial Services, Inc. is under investigation for potential violations of federal securities laws related to its mortgage recapture efforts as interest rates declined [1][2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is investigating whether PennyMac misrepresented its ability to recapture customers refinancing their mortgages during a period of declining interest rates [3]. - The investigation follows PennyMac's claims of improved recapture rates, which may not align with actual performance [2][3]. Group 2: Financial Performance and Stock Impact - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, revealing that increased origination capacity did not translate into expected refinancing business due to heightened competition [4]. - Following the earnings call, PennyMac's stock price dropped over 37%, from $140.70 per share to as low as $93.50 per share [4].

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Coupang, Inc. (NYSE: CPNG). Shareholders who purchased shares of CPNG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/coupang-inc-loss-submission-form-2/?id=183335&from=3 CLASS PERIOD: May 7, 2025 to Dece ...

Core Viewpoint - Scott+Scott Attorneys at Law LLP is investigating potential misleading statements and omissions by Navan, Inc. and its executives, which may violate federal securities laws [1]. Company Overview - Navan, Inc. is a corporate travel and expense management company [2]. - The company went public on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share [2]. Financial Performance - On December 15, 2025, Navan reported a GAAP loss from operations of $79 million for Q3 fiscal 2026, compared to a loss of $19 million in the same period the previous year [3]. - The GAAP operating margin for the same quarter was -41%, a decline from -13% year-over-year [3]. Stock Market Reaction - Following the release of the financial results and the announcement of the CFO's resignation, Navan's stock price dropped by $1.74, or 11.9%, closing at $12.90 per share on December 16, 2025 [4].

Core Viewpoint - PennyMac Financial Services, Inc. is under investigation for potential violations of federal securities laws related to its mortgage recapture efforts as interest rates declined [1][2][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into PennyMac for possibly misrepresenting its ability to recapture customers refinancing their mortgages [3]. - The investigation follows PennyMac's claims of improved recapture rates during a period of declining interest rates [2]. Group 2: Financial Performance and Stock Impact - On January 29, 2026, PennyMac reported disappointing financial results for Q4 2025, which included revelations from senior management about increased competition in the mortgage origination market [4]. - The stock price of PennyMac dropped over 37%, falling from $140.70 per share to as low as $93.50 per share following the earnings call [4].

Core Viewpoint - REGENXBIO Inc. is under investigation for potential violations of federal securities laws following the FDA's clinical holds on its RGX-111 and RGX-121 programs, which resulted in a significant decline in the company's share price by 30-35% [1]. Regulatory Compliance - Public companies are required to disclose material information to investors as per SEC disclosure rules, specifically through Form 8-K, which allows for the reporting of material events not covered by other items [2]. - Rule 10b-5 under the Securities Exchange Act of 1934 prohibits both material misstatements and omissions in securities transactions, emphasizing the need for complete and accurate disclosures [2]. Company Communication - During the Q3 2025 earnings call, CEO Curran Simpson highlighted positive regulatory interactions, noting that the FDA completed inspections with no observations, which may have created an asymmetric view of the company's regulatory status by not disclosing safety concerns being evaluated [3]. - The Q3 2025 earnings call transcript notably lacked any discussion regarding the RGX-111 program for MPS I, despite it being a significant pipeline asset that later faced the same FDA clinical hold, raising concerns about the completeness of information provided to shareholders [4].

Core Viewpoint - Corcept Therapeutics is under investigation for potential securities law violations following a disappointing response from the FDA regarding its drug application for relacorilant, leading to a significant drop in its stock price [1][2][3]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The company expressed surprise and disappointment at this outcome [2]. - Following the announcement, Corcept's stock price fell by $35.40, closing at $34.80 per share on the same day [2]. - On January 30, 2026, it was reported that Corcept's shares fell an additional 16% after a corrected CRL indicated that the FDA had previously warned the company against submitting its drug application [3]. Company Background - Corcept Therapeutics is based in Redwood City, California, and focuses on developing treatments for patients with severe metabolic and psychiatric disorders [1]. - Berman Tabacco, the law firm investigating Corcept, has a history of prosecuting securities cases on behalf of investors and has been recognized for its work in this field [4].

New York, New York--(Newsfile Corp. - January 29, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Wealthfront Corporation (NASDAQ: WLTH) for potential violations of the federal securities laws. If you invested in Wealthfront, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/wealthfront-corporation-class-action.Why is Wealthfront Being Investigated for Violations of the Federal Securities Laws? Wealthfront is an onli ...

Core Insights - The complaint alleges that SLM and its executives violated federal securities laws by making false or misleading statements regarding the company's delinquency rates and loss mitigation programs [2] - A report from TD Cowen indicated that SLM's delinquencies increased by 49 basis points month-over-month in July 2025, contradicting previous assurances from the company's executives [3] - Following the negative report, SLM's stock price dropped by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [3] Legal Proceedings - The lead plaintiff in the class action lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4] - Any member of the putative class can move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [4] Additional Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding SLM's conduct to come forward, including whistleblowers and former employees [5]